留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

辅助性T细胞17/调节性T细胞在类风湿关节炎免疫调节中的作用

李忱 刘晋河 董振华

李忱, 刘晋河, 董振华. 辅助性T细胞17/调节性T细胞在类风湿关节炎免疫调节中的作用[J]. 协和医学杂志, 2016, 7(1): 53-56. doi: 10.3969/j.issn.1674-9081.2016.01.011
引用本文: 李忱, 刘晋河, 董振华. 辅助性T细胞17/调节性T细胞在类风湿关节炎免疫调节中的作用[J]. 协和医学杂志, 2016, 7(1): 53-56. doi: 10.3969/j.issn.1674-9081.2016.01.011

辅助性T细胞17/调节性T细胞在类风湿关节炎免疫调节中的作用

doi: 10.3969/j.issn.1674-9081.2016.01.011
详细信息
    通讯作者:

    刘晋河 电话:010-69155332, E-mail:liujh1105@aliyun.com

  • 中图分类号: R593.2;R392.3

  • [1] Aarvak T, Chabaud M, Miossec P, et al. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells[J]. J Immunol, 1999, 162:1246-1251. http://ckj.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=jimmunol&resid=162/3/1246
    [2] Wang W, Shao S, Jiao Z, et al. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis[J]. Rheumatol Int, 2012, 32:887-893. doi:  10.1007/s00296-010-1710-0
    [3] Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells[J]. N Engl J Med, 2009, 361:888-898. doi:  10.1056/NEJMra0707449
    [4] Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium[J]. Arthritis Rheum, 1999, 42:963-970. doi:  10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E
    [5] Ziolkowska M, Koc A, Luszczykiewicz G, et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism[J]. J Immunol, 2000, 164:2832-2838. doi:  10.4049/jimmunol.164.5.2832
    [6] Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis[J]. Ann Rheum Dis, 2006, 65(Suppl 3):iii29-iii33. http://pubmedcentralcanada.ca/pmcc/articles/PMC1798387/
    [7] Kirkham BW, Lassere MN, Edmonds JP, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort)[J]. Arthritis Rheum, 2006, 54:1122-1131. doi:  10.1002/art.21749
    [8] Kwok SK, Cho ML, Park MK, et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis[J]. Arthritis Rheum, 2012, 64:740-751. doi:  10.1002/art.33390
    [9] van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid[J]. Arthritis Rheum, 2004, 50: 2775-2785. doi:  10.1002/art.20499
    [10] Möttönen M, Heikkinen J, Mustonen L, et al. CD4+CD25+T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis[J]. Clin Exp Immunol, 2005, 140:360-367. doi:  10.1111/j.1365-2249.2005.02754.x
    [11] Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood[J]. Rheumatology (Oxford), 2006, 45:1210-1217. doi:  10.1093/rheumatology/kel089
    [12] Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy[J]. J Exp Med, 2004, 200:277-285. doi:  10.1084/jem.20040165
    [13] Nie H, Zheng Y, Li R, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis[J]. Nat Med, 2013, 19:322-328. doi:  10.1038/nm.3085
    [14] Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+T lymphocytes[J]. J Immunol, 2007, 178:732-739. doi:  10.4049/jimmunol.178.2.732
    [15] Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells[J]. Blood, 2006, 108:253-261. http://intimm.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=bloodjournal&resid=108/1/253
    [16] Atzeni F, Benucci M, Sallì S, et al. Different effects of biological drugs in rheumatoid arthritis[J]. Autoimmun Rev, 2013, 12:575-579. doi:  10.1016/j.autrev.2012.10.020
    [17] Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta[J]. J Exp Med, 2007, 204:33-39. doi:  10.1084/jem.20061531
    [18] McGovern JL, Nguyen DX, Notley CA, et al. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy[J]. Arthritis Rheum, 2012, 64:3129-3138. doi:  10.1002/art.34565
    [19] Aravena O, Pesce B, Soto L, et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-gamma-producing NK cell and regulatory T cell subsets[J]. Immunobiology, 2011, 216:1256-1263. doi:  10.1016/j.imbio.2011.07.006
    [20] Tanaka T. Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?[J].Immunotherapy, 2013, 5:695-697. doi:  10.2217/imt.13.47
    [21] Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement[J]. Ann Rheum Dis, 2013, 72:583-589. doi:  10.1136/annrheumdis-2012-202470
    [22] Lequerré T, Avenel G, Vittecoq O. Therapeutic update in rheumatoid arthritis[J]. Rev Med Intern, 2013, 34:754-762. doi:  10.1016/j.revmed.2013.09.010
    [23] Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis[J]. Sci Transl Med, 2010, 2:52ra72.doi: 10.1126/scitranslmed.3001107.
    [24] Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study[J]. Arthritis Rheum, 2010, 62:929-939. doi:  10.1002/art.27334
    [25] Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand[J]. Nature, 2011, 472:491-494. doi:  10.1038/nature10075
    [26] Kelchtermans H, Geboes L, Mitera T, et al. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis[J]. Ann Rheum Dis, 2009, 68:744-750. doi:  10.1136/ard.2007.086066
    [27] Wright GP, Stauss HJ, Ehrenstein MR. Ehrenstein. Therapeutic potential of Tregs to treat rheumatoid arthritis[J]. Semin Immunol, 2011, 23:195-201. doi:  10.1016/j.smim.2011.07.004
    [28] Ju JH, Heo YJ, Cho ML, et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells[J]. Arthritis Rheum, 2012, 64:3543-3552. doi:  10.1002/art.34601
  • 加载中
计量
  • 文章访问数:  97
  • HTML全文浏览量:  35
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-06-05
  • 刊出日期:  2016-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!